These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21120161)

  • 1. Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia.
    Kim YK; Kim HN; Lee SR; Ahn JS; Yang DH; Lee JJ; Lee IK; Shin MG; Kim HJ
    Korean J Hematol; 2010 Mar; 45(1):36-45. PubMed ID: 21120161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations.
    Yoon JH; Kim HJ; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Genes Chromosomes Cancer; 2015 Aug; 54(8):489-499. PubMed ID: 26054017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
    Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
    Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incidence and prognostic effect of Fms-like tyrosine kinase 3 gene internal tandem and nucleolar phosphoprotein 1 genes in acute myeloid leukaemia: A PRISMA-compliant systematic review and meta-analysis.
    Liu H; Zhang X; Li M; Zhou W; Jiang G; Yin W; Song C
    Medicine (Baltimore); 2020 Dec; 99(51):e23707. PubMed ID: 33371116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.
    Pratcorona M; Brunet S; Nomdedéu J; Ribera JM; Tormo M; Duarte R; Escoda L; Guàrdia R; Queipo de Llano MP; Salamero O; Bargay J; Pedro C; Martí JM; Torrebadell M; Díaz-Beyá M; Camós M; Colomer D; Hoyos M; Sierra J; Esteve J;
    Blood; 2013 Apr; 121(14):2734-8. PubMed ID: 23377436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.
    Chen F; Sun J; Yin C; Cheng J; Ni J; Jiang L; Wang Q; Yu G; Wei Y; Liu X; Sun J; Carter BZ; Jiang X
    Bone Marrow Transplant; 2020 Apr; 55(4):740-748. PubMed ID: 31645666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of FLT3 Internal Tandem Duplications in Adult Syrian Patients with Acute Myeloid Leukemia and Normal Karyotype.
    Al-Arbeed IF; Wafa A; Moassass F; Al-Halabi B; Al-Achkar W; Abou-Khamis I
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3245-3251. PubMed ID: 34711001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics.
    How J; Sykes J; Minden MD; Gupta V; Yee KW; Schimmer AD; Schuh AC; Kamel-Reid S; Brandwein JM
    Blood Cancer J; 2013 May; 3(5):e116. PubMed ID: 23708641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
    Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
    Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
    Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
    Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
    Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
    Döhner H; Wei AH; Roboz GJ; Montesinos P; Thol FR; Ravandi F; Dombret H; Porkka K; Sandhu I; Skikne B; See WL; Ugidos M; Risueño A; Chan ET; Thakurta A; Beach CL; Lopes de Menezes D
    Blood; 2022 Oct; 140(15):1674-1685. PubMed ID: 35960871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
    Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
    Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.
    Haferlach T; Bacher U; Alpermann T; Haferlach C; Kern W; Schnittger S
    Leuk Res; 2012 Jan; 36(1):51-8. PubMed ID: 21621842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
    Pasic I; Da'na W; Lam W; Law A; Lipton JH; Viswabandya A; Kim DD; Thyagu S; Messner HA; Michelis FV
    Eur J Haematol; 2019 Apr; 102(4):368-374. PubMed ID: 30706524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
    Miyashita N; Onozawa M; Yoshida S; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Hirabayashi S; Fujisawa S; Mori A; Ota S; Kakinoki Y; Tsutsumi Y; Yamamoto S; Miyagishima T; Nagashima T; Ibata M; Wakasa K; Haseyama Y; Fujimoto K; Ishihara T; Sakai H; Kondo T; Teshima T
    Int J Hematol; 2023 Jul; 118(1):36-46. PubMed ID: 36853451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.